Revive Therapeutics: Developing Novel Treatments for TBI, Addiction, and COVID-19
Revive Therapeutics (CSE:RVV) is in the spotlight these days for good reason, thanks to a portfolio of prized intellectual property in the psychedelics field, as well as a COVID-19 drug candidate. In March of last year, Revive acquired Psilocin Pharma for its psilocybin-based IP and treatments. Psilocin founder Derrick Welsh now spearheads Revive’s psychedelics division.…
